Inactive Instrument

BIGN HLDG

BTH

AU000000BTH6

Bigtincan Holdings Limited Provides Financial Results Outlook for Fiscal Year 2023

Published on 21/07/2023 at 01:01

Bigtincan Holdings Limited provided financial results outlook for fiscal year 2023. For the period, the company expected revenue in the range of $123 million - 128 million.

Latest news about BIGN HLDG

ASX Preview: Australian Shares Set to Surge After Tariff Pause Fuels Wall Street Rally	04-09	MT
Bigtincan Holdings Limited(ASX:BTH) dropped from S&P/ASX Emerging Companies Index	04-09	CI
Bigtincan Holdings Says Schemes of Arrangement Become Legally Effective	04-09	MT
ASX Midday Sector Update: Information Technology Stocks Lead Broad-Based Rebound	04-08	MT
New South Wales Supreme Court Approves the Acquisition of Bigtincan by Vector Capital Entity	04-08	MT
Bigtincan Holdings Limited - Shareholder/Analyst Call	04-03
Bigtincan Holdings Limited - Shareholder/Analyst Call	04-03
Bigtincan Holdings Limited - Shareholder/Analyst Call	04-03
Bigtincan Holdings' Shareholders to Vote on Acquisition Proposal by Big Wombat; Shares Fall 5%	03-24	MT
Bigtincan Holdings Says No Adjustment to Share Scheme Consideration Required in Connection with Acquisition by Big Wombat	03-18	MT
Supreme Court Orders Meeting for Bigtincan Holdings' Proposed Acquisition by Big Wombat	02-28	MT
Bigtincan Holdings Limited - Shareholder/Analyst Call	02-26
Bigtincan Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2024	02-24	CI
Bigtincan Holdings Limited Appoints Akash Agarwal as Director	12-03	CI
Bigtincan Holdings Limited cancelled the acquisition of Investcorp India Acquisition Corp in a reverse merger transaction.	11-28	CI
Bigtincan Holdings Limited - Shareholder/Analyst Call	11-28
Bigtincan Holdings Limited announced that it expects to receive AUD 37.3 million in funding	20/10/24	CI
Bigtincan Holdings Limited Announces Retirement of Inese Kingsmill as Non-Executive Director, Effective in November 2024	11/10/24	CI
Bigtincan Receives Non-Binding Business Combination Proposal from Investcorp India Acquisition	02/10/24	CI
Bigtincan Holdings Limited proposed to acquire Investcorp India Acquisition Corp in a reverse merger transaction for approximately AUD 570 million.	01/10/24	CI
Bigtincan Receives Acquisition Offer from Vector Capital Management	17/09/24	MT
Vector Capital Management, L.P. made an offer to acquire Bigtincan Holdings Limited for approximately AUD 140 million.	16/09/24	CI
Bigtincan Holdings Limited, 2024 Earnings Call, Aug 29, 2024	29/08/24
Bigtincan Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2024	28/08/24	CI
Bigtincan Holdings Rejects Vector's Revised Acquisition Offer	20/06/24	MT

Beta Pharmaceutical Limited is a Australia-based biopharmaceutical company. The Company is focused on the identification, development and commercialization of products and therapies targeting the chemoprevention and treatment of breast cancer. The Company is working in collaboration with scientists at the College of Pharmacy, University of Louisiana at Monroe in southern the United States of America (ULM) to develop cancer chemopreventive agents using natural phytonutrients, called tocotrienols as treatments for breast cancers. Funded by Beta Pharmaceutical Limited, the applied research programme with ULM includes four laboratories and is known as the Breast Cancer and Health Project, which has been underway.

Employees

495

Sector

More about the company

BIGN HLDG

Equities

BTH

AU000000BTH6

Bigtincan Holdings Limited Provides Financial Results Outlook for Fiscal Year 2023

Latest news about BIGN HLDG

Chart BIGN HLDG

Company Profile